|本期目录/Table of Contents|

[1]陈秋静,何玉虎,丁风华等.血清高迁移率族蛋白2与冠状动脉支架内再狭窄的关系研究[J].国际心血管病杂志,2017,05:305-308316.
　CHEN Qiujing,HE Yuhu,DING Fenghua,et al.Association of serum HMGB2 levels with in-stent restenosis[J].International Journal of Cardiovascular Disease,2017,05:305-308316.
点击复制

血清高迁移率族蛋白2与冠状动脉支架内再狭窄的关系研究(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2017年05期
页码:
305-308316
栏目:
临床研究
出版日期:
2017-10-20

文章信息/Info

Title:
Association of serum HMGB2 levels with in-stent restenosis
作者:
陈秋静; 何玉虎; 丁风华等
200025 上海交通大学医学院附属瑞金医院心内科
Author(s):
CHEN Qiujing;  HE Yuhu;  DING Fenghua;  LU Lin
Department of Cardiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
关键词:
高迁移率族蛋白2;  支架内再狭窄;  内膜增生
Keywords:
High-mobility group box-2;  In-stent restenosis;  Neointimal hyperplasia
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2017.05.015
文献标识码:
-
摘要:
目的:探讨血清高迁移率族蛋白2(HMGB2)与冠状动脉支架内再狭窄(ISR)的关系。方法:在行经皮冠状动脉介入 术并于约1年后行冠脉动脉造影复查的2 513例患者中,262例为ISR患者(ISR组),于剩余患者中随机入选298例无ISR的冠 心病患者作为对照(无ISR组)。检测患者血清HMGB2水平及生化指标,并收集患者的临床资料。多变量logistic回归分析 发生ISR的独立危险因素。结果:ISR组血清HMGB2水平显著高于无ISR组(P<0.001)。与无ISR组相比,IS
Abstract:
Objective:To investigate the association of serum high-mobility group box-2(HMGB2)levels with in-stent restenosis(ISR).Methods:From 2 513 patients undergoing percutaneous coronary artery intervention and follow-up angiography at approximately one year

参考文献/References

[1] Dangas GD, Claessen BE, Caixeta AA, et al. In-stent restenosis in the drug-eluting stent era[J]. J Am Coll Cardiol, 2010, 56(23):1897-1907.
[2] Kaul U, Bangalore S, Seth A, et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes[J]. N Engl J Med, 2015, 373(18):1709-1719.
[3] Alfonso F, Byrne RA, Rivero FA. Current treatment of in-stent restenosis[J]. J Am Coll Cardiol, 2014, 63(24):2659-2673.
[4] Cai J, Wen J, Bauer E, et al. The role of HMGB1 in cardiovascular biology: danger signals[J]. Antioxid Redox Signal, 2015, 23(17):1351-1369.
[5] Cai J, Yuan H, Wang Q, et al. HMGB1-driven inflammation and intimal hyperplasia after arterial injury involves cell-specific actions mediated by TLR4[J]. Arterioscler Thromb Vasc Biol, 2015, 35 (12):2579-2593.
[6] Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease[J]. Mol Aspects Med, 2014, 40:1-116.
[7] Barreiro-Alonso A, Lamas-Maceiras M, Rodríguez-Belmonte E, et al. High mobility group B proteins, their partners, and other redox sensors in ovarian and prostate cancer[J]. Oxid Med Cell Longev, 2016, 2016:5845061.
[8] Yanai H, Ban T, Taniguchi T. High-mobility group box family of proteins: ligand and sensor for innate immunity[J]. Trends Immunol, 2012, 33(12):633-640.
[9] Yanai H, Ban T, Wang Z, et al. HMGB proteins function as universal sentinels for nucleic-acid- mediated innate immune responses[J]. Nature, 2009, 462(7269):99-103.
[10] Takaishi H, Kanai T, Nakazawa A, et al. Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins(HMGB1/HMGB2)antibodies and anti-saccharomyces cerevisiae antibodies(ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenoty[J]. J Gastroenterol, 2012, 47(9):969-977.
[11] Kwon JH, Kim J, Park JY, et al. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma[J]. Clin Cancer Res, 2010, 16(22):5511- 5521.
[12] Yang H, Tracey KJ. Targeting HMGB1 in inflammation[J]. Biochim Biophys Acta, 2010, 1799(1/2):149- 156.
[13] Montezano AC, Touyz RM. Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research[J]. Antioxid Redox Signal, 2014, 20(1):164-182.
[14] Liu ZH, Dai DP, Ding FH, et al. Association of serum HMGB2 level with MACE at 1 mo of myocardial infarction: aggravation of myocardial ischemic injury in rats by HMGB2 via ROS[J]. Am J Physiol Heart Circ Physiol, 2017, 312(3):H422-H436.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81400215)
通信作者:陆林,Email:rjlulin1965@163.com
更新日期/Last Update: 2017-10-20